Antigen Activation

Article

Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.

Related Videos
Related Content

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.